Graphical Abstract Highlights d HIF1a reduces intracellular aspartate levels d HIF1a impairs oxidative and reductive aspartate biosynthesis d The aspartate-generating GOT1 and GOT2 enzymes are repressed by HIF1a d Aspartate supplementation counteracts the antiproliferative influence of HIF1a In Brief Melé ndez-Rodríguez et al. show that HIF1a impairs oxidative and reductive aspartate biogenesis, which consequently drives HIF1a-dependent suppression of tumor cell proliferation. Mechanistically, HIF1a represses the aspartate-producing enzymes GOT1 and GOT2 in several biological settings, including human VHL-deficient renal cell carcinoma, in which HIF1a can act as a tumor suppressor.
INTRODUCTION
The biosynthesis of aspartate is central in cancer cell autonomous proliferation because it is essential not only for protein synthesis but also for nucleotide biosynthesis in proliferating cells (Birsoy et al., 2015; Lane and Fan, 2015; Sullivan et al., 2015) . Circulating levels of aspartate are low compared with other amino acids (Mayers and Vander Heiden, 2015) , and it is presumed that most cells largely rely on intracellular aspartate biosynthesis to sustain cellular growth. Aspartate biosynthesis is driven largely by glucose-or glutamine-dependent refilling of the tricarboxylic acid (TCA) cycle to replenish mitochondrial TCA intermediate oxaloacetate, which is subsequently converted to aspartate through the activity of mitochondrial glutamic-oxaloacetic transaminase (GOT2). Alternatively, cells can also use reductive glutamine metabolism to generate aspartate through the cytosolic GOT1 isoform (Birsoy et al., 2015) . This function of GOT1 is relevant to sustain aspartate biosynthesis and cell proliferation when mitochondrial-dependent aspartate biosynthesis is compromised (Birsoy et al., 2015) . However, the intracellular signals that rewire aspartate biosynthesis to attenuate cell growth remain largely unknown.
Hypoxia-inducible factors (HIFs) are key transcriptional regulators of the adaptive tumor cellular response to low oxygen tension. Under normoxic conditions, critical key proline residues in HIFa subunits are hydroxylated by prolyl hydroxylases (PHD1-3), which ultimately leads to their recognition by the von Hippel-Lindau (VHL) protein and their consequent degradation by the proteasome (Epstein et al., 2001; Ivan et al., 2001; Jaakkola et al., 2001; Wang et al., 1995) . In hypoxic conditions, PHD activity is restrained, and therefore VHL is unable to recognize HIFa subunits, leading to their nuclear accumulation. HIF1a can act as a repressor of tumor cell proliferation in different biological settings (Carmeliet et al., 1998; Gordan et al., 2007; Hubbi et al., 2013) and has been widely studied in clear cell renal cell carcinoma (CCRCC), which is characterized by VHL inactivation and consequent constitutive normoxic activation of the HIF1a (Gordan et al., 2007; Kaelin, 2008) . In this line, a large proportion of CCRCCs harbor homozygous DNA deletions in the genomic region encompassing the HIF1a locus, resulting in a loss of HIF1a activity (Shen et al., 2011) .
To enable cells to adapt to low-oxygen environments, HIF1a increases glycolytic flux while simultaneously suppressing glucose-dependent TCA refilling and glucose-dependent citrate biosynthesis. Moreover HIF1a facilitates the biogenesis of citrate from glutamine through reductive carboxylation to support cell proliferation in hypoxic conditions and upon TCA cycle impairment (Fendt et al., 2013; Metallo et al., 2011; Mullen et al., 2011; Wise et al., 2011) . However, HIF1a represses cell autonomous proliferation, which led us to hypothesize that HIF1a could execute an additional metabolic control to override glutamine reductive carboxylation and therefore guarantee the suppression of cell proliferation. Indeed, HIF1a acts not only as a repressor of aspartate biosynthesis through glutamine oxidation but also as a simultaneous repressor of later steps in the glutamine reductive carboxylation pathway involved in cytosolic aspartate generation. In this line, HIF1a reduces the expression of key metabolic proteins involved in aspartate biogenesis, including the cytosolic and mitochondrial aspartate-producing enzymes GOT1 and GOT2. Significantly, aspartate supplementation suffices to relieve the suppression of cell proliferation upon HIF1a activation, highlighting the importance of diminished aspartate biosynthesis for the tumor-suppressive potential of HIF1a. In addition, we found that GOT1 and GOT2 are suppressed in VHL-deficient human renal carcinoma, for which HIF1a executes its tumor-suppressive potential. By identifying a role of HIF1a as a repressor of aspartate biosynthesis, we provide mechanistic insight into the molecular basis of its tumor-suppressor function through aspartate metabolic reprogramming.
RESULTS

HIF1a Reduces Aspartate Generation through Glutamine Oxidation
The intracellular molecular mechanisms that control aspartate biosynthetic pathways remain largely unknown. We questioned whether HIF1a, which acts as a suppressor of tumor cell proliferation, executes its antiproliferative effects through rewiring of aspartate metabolism. To unequivocally assess the role of HIF1a in aspartate metabolism, we restored HIF1a expression by transduction of a wild-type version of HIF1a in 786-O cells (786-O-HIF1a cells) and the corresponding control to generate 786-O-control cells as well as a mutant DNA-binding domain HIF1a (HIF1a bHLH*), lacking transcriptional activity (786-O-HIF1a bHLH* cells) ( Figure 1A ). Of note, to avoid an excessive ectopic HIF1a expression, we restored HIF1a to levels similar to endogenous HIF1a in cells exposed to hypoxia ( Figure S1A ). We confirmed that HIF1a was active in 786-O cells by measuring the expression of carbonic anhydrase IX (CAIX), a well-recognized HIF1a-dependent gene in CCRCC (Raval et al., 2005) . Accordingly, CAIX was expressed at higher levels in HIF1atransduced cells compared with both 786-O-HIF1a bHLH* and 786-O-control cells ( Figure 1A) . Moreover, ectopic expression of HIF1a, but not HIF1a bHLH*, inhibited the proliferation rate of 786-O cells ( Figure 1B ), in line with the tumor-suppressive potential of HIF1a.
Glutamine utilization has been shown to be relevant in CCRCC biology (Fendt et al., 2013; Gameiro et al., 2013; Metallo et al., 2011; Mullen et al., 2011; Shroff et al., 2015; Wise et al., 2011) . Glutamine is first converted to glutamate by the enzyme glutaminase and is subsequently converted to a-ketoglutarate (a-KG) to replenish the TCA cycle, which permits aspartate biosynthesis through glutamine oxidation (Altman et al., 2016; Birsoy et al., 2015; Buescher et al., 2015; Lane and Fan, 2015; Sullivan et al., 2015) . We next assessed the levels of total glutamate, a-KG, and aspartate as well as the relative contribution of glutamine-dependent metabolism to the generation of these metabolites using 13 C 5 -glutamine tracer analysis ( Figure 1C ) in 786-O cells upon HIF1a activation. Our analysis showed an increase of total glutamate levels, while a-KG was not significantly altered in 786-O-HIF1a cells with respect to controls ( Figure 1D ). In sharp contrast, 786-O-HIF1a cells showed a remarkable decrease in aspartate levels compared with control cells ( Figure 1D ). As outlined above, we also considered aspartate generation through glutamine oxidation, in which 13 C 5 -glutamine is converted first to labeled M+5 glutamate and M+5 a-KG, which the latter is subsequently converted to M+4 aspartate through the TCA cycle ( Figure 1C ). The total content of M+5 glutamate was elevated, while M+5 a-KG generated from 13 C 5 -glutamine was unchanged in 786-O-HIF1a cells compared with control cells ( Figure 1E ). However, we observed a remarkable decrease in the total content of M+4 aspartate in 786-O cells upon HIF1a activation ( Figure 1E ).
We next assessed whether this rewiring of aspartate biosynthesis also occurs in other cellular settings. Loss of HIF1a has been largely investigated in VHL-deficient renal cell carcinoma cells, but deletions affecting chromosome 14q including HIF1a locus have been also reported in other tumor types, such as melanoma (Shen et al., 2011) . Along this line, we found a spontaneously occurring subclone of melanoma cell line (UCDMel) with homozygous deletions of specific exons in the HIF1a locus (UCDMel-DH) ( Figures S1B and S4G ). In UCDMel-DH cells, we restored HIF1a activity by expressing a version of HIF1a lacking key proline hydroxylation P402 and P564 residues (HIF1a (P2)*) required for degradation in normoxia ( Figure 2A ). HIF1a (P2)* protein levels in UCDMel-DH cells were also comparable with endogenous HIF1a levels in cells exposed to hypoxia (Figure S1A) . As expected, HIF1a (P2)* expression induced CAIX expression ( Figure 2A ) and repressed cell autonomous proliferation compared with those cells expressing the mutant DNA-binding domain HIF1a (P2)* bHLH* and the corresponding control cells ( Figure 2B ). Total levels of glutamate were elevated, while total a-KG levels were modestly diminished in UCDMel-DH-HIF1a (P2*) cells compared with the corresponding control cells ( Figure 2C ). Importantly, similar to 786-O-HIF1a cells, aspartate levels were markedly lower compared with the corresponding control cells ( Figure 2C ). 13 C 5 -glutamine tracer analysis (Figure 1C) revealed that HIF1a (P2)* expression elevates total content of M+5 glutamate while M+5 a-KG was modestly diminished ( Figure 2D ). However, we also observed a remarkable decrease in the total content of M+4 aspartate in UCDMel-DH cells upon HIF1a activation ( Figure 2D ). Overall, these data allow us to conclude that HIF1a represses intracellular aspartate levels and that this effect can be attributed, at least partly, to diminished glutamine-dependent aspartate biosynthesis through glutamine oxidation.
HIF1a Represses Key Mitochondrial Proteins Involved in Aspartate Biosynthesis through Glutamine Oxidation
Aspartate biosynthesis through glutamine oxidation specifically requires the activity of GOT2, which converts oxaloacetate in the mitochondrion to aspartate (Birsoy et al., 2015; Coloff et al., 2016) . We thus assessed whether HIF1a represses GOT2 expression. Western blot analysis showed that GOT2 expression was lower in 786-O-HIF1a cells than in 786-O-HIF1a bHLH* mutant and 786-O-control cells ( Figure 3A ), and this was also found in UCDMel-DH-HIF1a (P2)* cells ( Figure 3B ). The expression of other aminotransferases such as phosphoserine aminotransferase (PSAT1), in which a-KG generation is coupled to non-essential amino acids (Coloff et al., 2016) , was unaltered or showed an opposite trend (Figures 3A and 3B and data not shown), suggesting that the effect of HIF1a is specific to GOT2. We also considered that GOT2 requires oxaloacetate as a substrate, which is generated from malate and fumarate in the TCA cycle. In this respect, the enrichment of M+4 fumarate and M+4 malate from 13 C 5 -glutamine was also significantly decreased by HIF1a activation in 786-O and UCDMel-DH cells ( Figures S2A and S2B ). In accordance with these data, we found that HIF1a markedly repressed the expression of subunit A of succinate dehydrogenase (SDH-A), the mitochondrial complex II enzyme that converts succinate to fumarate in the TCA cycle ( Figures 3A and 3B ). Indeed, mitochondrial complex II activity in 786-O-HIF1a cells was significantly lower compared with control cells ( Figure S2C ).
Consistent with these data, we found that normoxic expression of HIF1a (P2)* at levels similar to endogenous HIF1a levels in hypoxia ( Figure S1A ) also repressed GOT2 and SDH-A expression in other cell lines, such as HeLa and SKOV3 (Figures S3A and S3B) . In addition to VHL-deficient 786-O-like cells that lack endogenous HIF1a expression, some other VHL-deficient cells such as the widely used RCC4 cells show constitutive endogenous HIF1a expression. Therefore, we asked whether endogenous derived from 13 C 5 -glutamine in UCDMel-DH HIF1a (P2)* and control cells (n = 3). Data are shown as mean ± SEM. Statistical analysis was performed using two-tailed unpaired t test when comparing two groups and one-way ANOVA followed by Tukey's post hoc test when comparing three groups. *p < 0.05 and ***p < 0.001.
HIF1a activity in these VHL-deficient cells can also repress GOT2 and SDH-A expression. In this line, we also found that inhibition of HIF1a in RCC4 cells by silencing of endogenous HIF1a or restoration of VHL results in an increased expression of GOT2 and SDH-A ( Figures S3C and S3D ).
Collectively, these data show that constitutive normoxic HIF1a activation, which acts as a tumor suppressor in VHL-deficient tumor cells, represses key proteins involved in glutamine oxidationdependent aspartate biosynthesis such as GOT2.
HIF1a Reduces Aspartate Biosynthesis through Reductive Glutamine Metabolism
Aspartate biosynthesis can also take place in the cytosol via the GOT1 aminotransferase isoform, which requires oxaloacetate formed from citrate generated through reductive glutamine metabolism (Birsoy et al., 2015) ( Figure 1C ). Previous studies have shown that citrate generation through reductive glutamine metabolism is favored upon HIF1a stabilization (Fendt et al., 2013; Gameiro et al., 2013; Metallo et al., 2011; Mullen et al., 2011; Wise et al., 2011) . This shift to a reductive glutamine metabolism can be measured by the enrichment of M+5 citrate (generated through glutamine reductive carboxylation) relative to M+4 citrate (generated through glutamine oxidation). Indeed, an increased ratio of M+5 to M+4 citrate from 13 C 5 -glutamine is indicative of a shift from an oxidative to a reductive glutamine metabolism ) ( Figure 1C ). In this line, both 786-O-HIF1a and UCDMel-DH-HIF1a (P2)* cells showed significant increases in the enrichment of M+5 citrate relative to M+4 citrate in cells cultured in media containing 13 C 5 -glutamine, confirming that both cell types favor reductive carboxylation pathway for citrate generation upon HIF1a activation ( Figures S2D and S2E ). The reductive carboxylation pathway further converts M+5 citrate into M+3 aspartate (Figure 1C ). However, our data show that the total content of M+3 aspartate from 13 C 5 -glutamine was markedly reduced in 786-O-HIF1a cells as well as in UCDMel-DH-HIF1a (P2)* cells ( Figures 3C and 3D) .
Moreover, these findings suggest that HIF1a can actively inhibit later steps of this reductive pathway required for cytosolic aspartate generation. Accordingly, we found that the expression of cytosolic GOT1 was decreased upon HIF1a in RCC4 cells as well as restoration of VHL increased GOT1 expression (Figures S4C and S4D) . Finally, we explored whether HIF1a controls GOT1 and GOT2 not only when constitutively expressed under normoxia, as is observed in VHL-deficient tumor cells, but also under hypoxia. To do this, we used G55 human glioma cells, which diminished their proliferation rate and showed reduced levels of GOT1 and GOT2 under hypoxia ( Figures S4E and S4F ). We then silenced endogenous HIF1a to assess its role in the inhibition of cell proliferation and GOT1/2 expression in G55 cells under hypoxia. HIF1a silencing was effective, as measured by the loss of hypoxic CAIX expression ( Figure S4F ). Moreover, HIF1a silencing relieved the hypoxia-dependent inhibition of G55 proliferation ( Figure S4E ) and, importantly, counteracted the hypoxiadependent suppression of GOT1 and GOT2 expression (Figure S4F ). In agreement with these data, hypoxia did not reduce GOT1 and GOT2 expression in UCDMel-DH cells, which, as mentioned earlier, lack HIF1a activity and only induce the HIF2a isoform ( Figure S4G ).
Our data suggest that HIF1a reduces aspartate biosynthesis not only through inhibiting glutamine oxidation but also by attenuating reductive carboxylation, by repressing key players involved in these two aspartate biosynthetic pathways, such as GOT1 and GOT2. Therefore aspartate biosynthesis through reductive carboxylation upon HIF1a activation cannot compensate for the decline of aspartate generation through glutamine oxidation shown in Figures 1E and 2D .
Aspartate Supplementation Recovers Cell Proliferation upon HIF1a Activation
We next investigated whether intracellular aspartate decline upon HIF1a activation might be enough to explain the antiproliferative effect of HIF1a. Our earlier data showed that 786-O-HIF1a cells had significantly lower levels of aspartate than control cells ( Figure 1D) . Importantly, the addition of extracellular aspartate at concentration of 50 mM was sufficient to significantly stimulate the proliferation of 786-O-HIF1a cells but did not affect the proliferation of corresponding control cells ( Figure 4A ). The ability of aspartate to foster proliferation partially relies on its abil- ity to participate in the production of newly synthesized nucleotides. Consistent with this notion, we found that addition of a nucleoside mixture relieved the suppressed cell proliferation of 786-O-HIF1a cells without any significant effect on the proliferation rate of control cells ( Figure 4B ). This relief in cell proliferation upon supplementation with nucleosides was lower than the effect of aspartate (compare Figures 4A and 4B) , but aspartate is used not only for DNA synthesis but is also required for protein synthesis. It is thus conceivable that nucleosides have a lower potential to alleviate proliferation in HIF1a-expressing cells than aspartate. Finally, we assessed whether aspartate could also counteract the antiproliferative potential of HIF1a in UCDMel-DH cells. Aspartate supplementation also recovered the proliferation of UCDMel-DH-HIF1a (P2)* cells but without any significant effect on control UCDMel-DH cells ( Figure 4C) , which further demonstrate that the ability of aspartate to relieve proliferation is specifically manifested in HIF1a-expressing cells.
Altogether, our data suggest that inhibition of aspartate biogenesis executed by HIF1a provides a metabolic basis for its prominent role in suppressing autonomous cell proliferation in different cellular settings. Indeed, HIF1a represses several key metabolic players, including GOT1 and GOT2, to ensure the complete inhibition of aspartate biosynthesis through the glutamine reductive carboxylation and glutamine oxidation pathways.
GOT1 and GOT2 Are Profoundly Repressed in Human VHL-Defective CCRCC To evaluate the possible clinical implications of our data, we assessed the expression of GOT1 and GOT2 in CCRCC tumors, in which VHL activity is lost. We also included samples of non-clear renal cell carcinomas (NCRCC), which are renal carcinomas that retain VHL expression and accordingly are not characterized by constitutive HIFa activation. In total, we examined tissue samples from ten patients with CCRCC and six patients with NCRCC in parallel with adjacent healthy renal tissue from the same patient. As a specific control for HIF1a activity in these tumors, we analyzed the expression of CAIX, which is specifically driven by HIF1a, but not HIF2a, in CCRCC cell lines such as RCC4 cells ( Figure 4D ) (Raval et al., 2005) . Compared with healthy renal tissue, all the CCRCC samples analyzed showed elevated CAIX expression, whereas no CAIX expression was detectable in any of the NCRCC samples analyzed ( Figure 4E ). Importantly, GOT2 expression was repressed in all CCRCC samples, and GOT1 expression was also repressed in the majority (nine of ten) of these CCRCC samples ( Figure 4E ). In sharp contrast to the reduced expression of GOT1 and GOT2 in CCRCC, five of six NCRCC samples showed elevated GOT1 and GOT2 expression compared with adjacent healthy renal tissue ( Figure 4E ). Collectively, these findings further show that human CCRCC presents a profound and simultaneous repression of GOT1 and GOT2, highlighting the relevance of the HIF1a-dependent regulation of these key players in aspartate biosynthesis in human tumors and, particularly, in VHL-deficient renal cell carcinomas. Moreover, these data underscore the clinical value of GOT1 and GOT2 repression to differentiate CCRCC and NCRCC renal cancers.
Overall, our data show that HIF1a acts as a repressor of key mitochondrial and cytoplasmic players of aspartate biosynthesis, providing a metabolic basis for the suppression of tumor cell proliferation by HIF1a in different biological settings, including VHL-deficient human carcinomas.
DISCUSSION
Aspartate has been identified as a key metabolite for cell proliferation because of its role in nucleotide synthesis (Birsoy et al., 2015; Lane and Fan, 2015; Sullivan et al., 2015) . In this study, we provide evidence that HIF1a acts as a suppressor of tumor cell proliferation by controlling aspartate biosynthetic pathways. Importantly, HIF1a suppresses key players required for aspartate biosynthesis through glutamine oxidation, such as GOT2 and SDH-A. Consistent with previous studies, we found that citrate generated through glutamine reductive carboxylation is favored upon HIF1a activation (Fendt et al., 2013; Lorendeau et al., 2017; Metallo et al., 2011; Mullen et al., 2011; Wise et al., 2011) likely in an attempt to compensate for the reduced glucose-dependent citrate biosynthesis upon HIF1a activation. However, we found that HIF1a attenuates later steps in the glutamine reductive carboxylation pathway by suppressing key players of this pathway involved in cytosolic aspartate generation, such as GOT1. It was recently shown that glutamine reductive carboxylation can contribute to aspartate generation in some VHL-deficient tumor cells (Okazaki et al., 2017) . However, our data show not only that the glutamine reductive pathway does not compensate for the diminished aspartate generation through glutamine oxidation upon HIF1a activation, but that HIF1a actively limits aspartate biosynthesis through this reductive pathway involving suppression of cytosolic GOT1. Consequently, this simultaneous inhibition of oxidative and reductive pathways results in a remarkable decline in total aspartate upon HIF1a activation. In addition, it should be also considered that the simultaneous impact of HIF1a on GOT1 and GOT2 also might result into a repression on the malate-aspartate shuttle, because GOT1 also executes its well-recognized function in this shuttle by converting aspartate (generated by GOT2 in mitochondria) to oxaloacetate in the cytoplasm. Reduced glutamine oxidation metabolism can be compensated for in some tumor cells by an elevated activity of the shuttle that favors aspartate-dependent TCA cycle replenishment (Allen et al., 2016) , and therefore the ability of HIF1a to suppress both players in the shuttle will ensure its function as a tumor suppressor even in cellular scenarios characterized by compensatory malateaspartate shuttle overactivation. Importantly the inhibition of GOT1/2 expression in HIF1a-expressing cells was manifest not only in cellular in vitro settings but also in VHL-deficient human CCRCCs, which are characterized by sustained activation of HIF1a but not in NCRCCs which lack constitutive HIF1a activation. Thus, GOT1 and GOT2 repression represents a specific metabolic feature of CCRCC. These findings not only support the notion that the repressive HIF1a-GOT1/2 pathway is operative in vivo in human tumors but also underscore the clinical value of our data to differentiate between CCRCC and NCRCC renal cancers. Finally it should also be stated that a recent metabolomic study of CCRCC found that these tumors have low aspartate levels (Hakimi et al., 2016) , and in vivo studies showed glutamine metabolism to have a dominant role in sustaining CCRCC growth (Shroff et al., 2015) . It is therefore plausible that HIF1a counteracts glutamine-dependent metabolic pathways in order to act as a tumor suppressor in CCRCC.
Notably, the relevance of aspartate insufficiency imposed by HIF1a tumor-suppressive activity was demonstrated by the fact that aspartate supplementation relieved HIF1a-dependent suppression of cell proliferation. Cancer cells have limited ability to uptake aspartate compared with other metabolites (Birsoy et al., 2015; Garcia-Bermudez et al., 2018; Sullivan et al., 2015 Sullivan et al., , 2018 . In this line, previous studies have shown that aspartate is required at concentrations of 5-20 mM to restore proliferation of cells lacking mitochondrial activity (Birsoy et al., 2015; Sullivan et al., 2015) . However, some tumor cell types show basal expression of the high-affinity aspartate transporter SLC1A3 to import aspartate, and therefore lower doses are sufficient to restore proliferation of these cells when mitochondrial activity is compromised (Garcia-Bermudez et al., 2018) . In this study we found that aspartate doses required to increase proliferation in 786-O-HIF1a cells are lower than in UCDMel-DH cells, possibly related to the higher expression of SLC1A3 in 786-O than in UCDMel-DH cells (data not shown). In agreement with our data, it was shown that hypoxia reduces intracellular aspartate levels and that hypoxia-dependent suppression of cell proliferation can be recovered by aspartate supplementation (Garcia-Bermudez et al., 2018; Sullivan et al., 2018) . However, it should be highlighted that these studies considered that oxygen insufficiency might restrict aspartate biosynthesis through a direct impairment of electron transport chain function, limiting the generation of electron acceptors required for aspartate synthesis. Our data show that the hypoxia-dependent suppression of aspartate metabolism is not necessarily a consequence of a direct impact on mitochondrial activity but importantly also requires the HIF1a oxygen-sensing pathway that promotes multiple actions that compromise aspartate biosynthesis. Therefore these data show that HIF1a pathway couples cellular oxygen supply and aspartate biosynthesis.
In summary, our study identifies HIF1a as an inhibitor of aspartate biogenesis by repressing glutamine oxidation and reductive carboxylation pathways, effects that include the suppression of several metabolic players involved in aspartate production, such as GOT1 and GOT2. This pathway provides a molecular basis for the effect of HIF1a in suppressing tumor cell proliferation that is operative in several biological settings, including human CCRCC, for which HIF1a acts as a tumor suppressor.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell cultures
The HEK293T, 786-O, UCDMel-DH, HeLa, SKOV3, RCC4 and G55 cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM, HyClone, GE HealthCare) with the addition of 100 units/ml penicillin, 100 mg/ml streptomycin, 20 mM HEPES and 10% fetal bovine serum (FBS, Cultek). G55 cells were cultured in DMEM (ThermoFisher Scientific) supplemented with 10% fetal bovine serum (FBS, Merck). Cells were maintained at 37 C in an atmosphere of 5% CO 2 /95% air (normoxic conditions). To induce hypoxia, the cell culture dishes were placed at 0.5%-1% O 2 conditions. For supplementation assays, we used DMEM containing 10% dialyzed FBS (10,000 Mwt cut-off; F0392, Sigma), which was then supplemented with aspartate (A7219, Sigma-Aldrich) or a mixture of nucleosides (ES-008-D, Merck) when necessary. 
Clinical material
METHOD DETAILS
DNA constructs
To generate 786-O cells stably expressing HIF1a, we used a lentiviral vector pLVX-TetOne-Puro (Takara) harboring a wild-type version of HIF1a, as well as pLVX-TetOne-Puro-Luc as its corresponding control vector. As an additional control, we utilized a lentiviral vector encoding HIF1a bHLH*, a version of HIF1a into which we introduced a four amino acid substitution within the basic helixloop-helix (bHLH) domain that impedes its transcriptional activity (similar to the four amino acid substitution previously introduced into HIF2a (P2)* (Kondo et al., 2003) ). Cells were transduced and then selected with 1 mg/ml puromycin (to obtain resistant polyclonal cell pools) and treated with 1 mg/ml doxycycline (to induce the vector expression).
To generate UCDMel-DH, HeLa and SKOV3 cell lines stably expressing HIF1a, we used a retroviral vector pRV encoding a mutated version of HIF1a at positions P402 and P564 (HIF1a (P2)*), which therefore lacks critical proline residues and is therefore not recognized by VHL. Accordingly, this construct is constitutively active in normoxic conditions irrespective of the oxygen tension (Yan et al., 2007) . In addition to the empty vector pRV, as an additional control, we utilized a retroviral vector encoding HIF1a (P2)* bHLH*, a version of HIF1a (P2)* into which we introduced a four amino acid substitution within the basic helix-loop-helix (bHLH) domain that impedes its transcriptional activity (similar to the four amino acid substitution previously introduced into HIF2a (P2)* (Kondo et al., 2003) ).
Lentiviral pLVX-VHL and pGIPZ-shHIF1a vectors and their corresponding pLVX and pGIPZ-shSCR (Dharmacon) control vectors were used to generate stable transfectants of RCC4 cells. Cells were transduced and then selected with 1 mg/ml puromycin to obtain resistant polyclonal cell pools.
Viral infection
For retroviral infection, HEK293T cells seeded in p60 plates were transfected with 4 mg of each retroviral vector and 4 mg of the pCL-Ampho Retrovirus Packaging Vector (Imgenex) using Lipofectamine 2000 (Invitrogen). Cell culture supernatants were harvested 24 hours after transfection, filtered through a 0.45 mm filter, diluted (1:2) with fresh medium containing 8 mg/ml polybrene (final concentration) and added to the corresponding cells. This step was repeated on the next 2 days. For lentiviral infection, HEK293T cells seeded in p60 plates were transfected with 1.3 mg of pLP1, 0.9 mg of pLP2, 1.1 mg of VSVg and 3.3 mg of each lentiviral vector, following the same protocol as for retroviral infection.
siRNA-mediated gene silencing
The siRNA experiments were carried out using HIF1a siRNA (sc-35561, Santa Cruz Biotechnology), HIF2a siRNA (L-004814-00-0005, Dharmacon) and control siRNA (sc-37007, Santa Cruz Biotechnology). RCC4 cells seeded in p60 plates were transfected with 60 nM of the corresponding siRNA using Lipofectamine 2000 (Invitrogen). After 72 hours post-transfection, cells were collected and stored at À20 C until processing for western blot analysis.
Western blots and antibodies
Cells were lysed in Laemmli buffer. Proteins were resolved in 8% or 10% SDS-polyacrylamide gels and transferred to 0.45 mm nitrocellulose membranes. The membranes were blocked and probed with antibodies against: HIF2a (ab199, Abcam); HIF1a (610959,BD Transduction Laboratories); tubulin (T6199, Sigma); b-actin (A3854, Sigma); VDAC1/Porin (ab15895, Abcam); GOT2 (HPA018139, Sigma Aldrich); GOT1 (14886-1-AP, ProteinTech); PSAT1 (PA5-22124, Thermo Fisher); SDH-A (ab137040, Abcam); and CAIX (sc-365900, Santa Cruz Biotechnology). Immunoreactivity was detected by enhanced chemiluminiscence (Clarity, BioRad; and Super-Signal West Femto Maximum Sensitivity Substrate, Thermo Scientific) and visualized on a digital luminescent image analyzer (Image Quant LAS4000 Mini; GE Healthcare).
Cell proliferation analysis
For cell proliferation assays, 40,000 UCDMel-DH cells or 20,000 786-O cells were seeded per well in 6-well plates. After 72 hours for UCDMel-DH cells or 96 hours for 786-O cells, they were trypsinized and collected in the medium and live cells per well were counted manually with Neubauer Chamber.
For cell proliferation recovery assays with UCDMel-DH and 786-O cells, after 6 hours from seeding them, the medium was changed to medium supplemented with dialyzed FBS and with or without aspartate (5 mM or 50 mM, respectively) or a mixture of nucleosides (1x working concentration). Then cells were grown for a further 72 or 96 hours and collected and counted as described before. Data were expressed as the percentage of proliferation recovery relative to equivalent cells cultured in non-supplemented medium.
G55 (30,000 cells) were seeded per well in 12-well plate. After 6 days later, cells were trypsinized and collected in the medium, and live cells per well were counted by CASY (OMNI Life Science).
13
C 5 -glutamine tracer analysis The 13 C 5 -glutamine tracer (Sigma-Aldrich) was added to cells grown to confluency. The medium was changed for unlabeled medium 1 hour before adding the 13 C 5 -glutamine medium. Cells were exposed to 13 C 5 -glutamine in medium containing dialyzed FBS for 4 hours, after which time the metabolites were extracted. Control cells were maintained in unlabeled media in parallel to determine e3 Cell Reports 26, 2257-2265.e1-e4, February 26, 2019
